Skip to main content
. Author manuscript; available in PMC: 2018 May 8.
Published in final edited form as: Atherosclerosis. 2014 Sep 30;237(1):314–318. doi: 10.1016/j.atherosclerosis.2014.09.023

Table 2.

Diagnostic characteristics of Guideline-Based Statin Eligibility for CCTA-Detected CAD

Sensitivity Specificity PPV NPV Balanced Accuracy*
2004 ATP III 27.3
(18.3–37.8)
83.2
(74.4–89.9)
58.5
(42.1–73.7)
56.8
(48.4–64.9)
55.2
(49.3–61.2)
2013 ACC/AHA
(7.5%)
53.4
(42.5–64.1)
70.3
(60.4–79.0)
61.0
(49.2–72.0)
63.4
(53.8–72.3)
61.9
(55.0–68.7)
2013 ACC/AHA
(5%)
71.6
(61.0–80.7)
61.4
(51.2–70.9)
61.8
(51.6–71.2)
71.3
(60.6–80.5)
66.5
(59.8–73.2)
2011 European 34.1
(24.3–45.0)
86.1
(77.8–92.2)
68.2
(52.4–81.4)
60.0
(51.5–68.0)
60.1
(54.1–66.1)

95% Confidence Intervals are in brackets;

*

Balanced Accuracy = Area under the receiver operating characteristic curve = (Sensitivity + Specificity)/2

HHS Vulnerability Disclosure